A carregar...

Toxicity management for patients receiving novel T-cell engaging therapies

PURPOSE OF REVIEW: Recent clinical trials using T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cells, as well as engineered T cells that express targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful proof of c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barrett, David M., Teachey, David T., Grupp, Stephan A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4198063/
https://ncbi.nlm.nih.gov/pubmed/24362408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOP.0000000000000043
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!